Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Moderate to Severe Plaque-type Psoriasis Clear all

Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550, Placebo/CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Birmingham, Alabama • Irvine, California • San Diego, California + 25 more

Source: ClinicalTrials.gov public record

Updated Sep 18, 2014 · Synced May 21, 2026, 7:14 PM EDT

Completed Not applicable Interventional Results available

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293

View directory record Official record

Conditions: Psoriasis
Interventions: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Source: ClinicalTrials.gov public record

Updated Dec 25, 2016 · Synced May 21, 2026, 7:14 PM EDT

Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more

Source: ClinicalTrials.gov public record

Updated Jun 25, 2017 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595

View directory record Official record

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more

Source: ClinicalTrials.gov public record

Updated Dec 19, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions: AIN457 150 mg, AIN457 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 28
States / cities: Fresno, California • Pasadena, California • San Francisco, California + 24 more

Source: ClinicalTrials.gov public record

Updated May 24, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345

View directory record Official record

Conditions: Chronic Plaque Psoriasis, Psoriasis
Interventions: M923, Humira; Biological
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 20 more

Source: ClinicalTrials.gov public record

Updated Oct 16, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687

View directory record Official record

Conditions: Plaque-type Psoriasis
Interventions: Placebo, Secukinumab 150mg, Secukinumab 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more

Source: ClinicalTrials.gov public record

Updated Sep 26, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580

View directory record Official record

Conditions: Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: MSB11022, Humira®; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years and older

Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Dec 26, 2023 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab low dose, secukinumab high dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years

Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more

Source: ClinicalTrials.gov public record

Updated May 15, 2025 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567

View directory record Official record

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 10, 2022 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Source: ClinicalTrials.gov public record

Updated Jan 23, 2013 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612

View directory record Official record

Conditions: Plaque-type Psoriasis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more

Source: ClinicalTrials.gov public record

Updated Jan 3, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865

View directory record Official record

Conditions: Psoriasis
Interventions: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more

Source: ClinicalTrials.gov public record

Updated Jul 6, 2017 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

NCT05190419

View directory record Official record

Conditions: Psoriasis, Skin Diseases
Interventions: Orismilast modified release tablets, Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 15, 2024 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564

View directory record Official record

Conditions: Psoriasis
Interventions: Alefacept; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Source: ClinicalTrials.gov public record

Updated Sep 10, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 50
States / cities: Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more

Source: ClinicalTrials.gov public record

Updated Dec 25, 2018 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01309737

View directory record Official record

Conditions: Psoriasis
Interventions: CP-690,550, Placebo/CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more

Source: ClinicalTrials.gov public record

Updated Sep 18, 2014 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457

View directory record Official record

Conditions: Psoriasis
Interventions: Ixekizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 31
States / cities: Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more

Source: ClinicalTrials.gov public record

Updated Sep 23, 2019 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional Results available

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

NCT03384745

View directory record Official record

Conditions: Psoriasis
Interventions: M1095 (Sonelokimab), Placebo, Secukinumab; Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more

Source: ClinicalTrials.gov public record

Updated Aug 2, 2021 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

NCT03047395

View directory record Official record

Conditions: Psoriasis
Interventions: risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 2,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 79
States / cities: Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more

Source: ClinicalTrials.gov public record

Updated Dec 10, 2024 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982

View directory record Official record

Conditions: Chronic Plaque Type Psoriasis
Interventions: AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more

Source: ClinicalTrials.gov public record

Updated Jul 20, 2017 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02207231

View directory record Official record

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 26
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 23 more

Source: ClinicalTrials.gov public record

Updated Jul 22, 2021 · Synced May 21, 2026, 7:14 PM EDT

Terminated Phase 2 Interventional Results available

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

NCT02201524

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: PF-04965842, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 35
States / cities: Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 28 more

Source: ClinicalTrials.gov public record

Updated Oct 4, 2016 · Synced May 21, 2026, 7:14 PM EDT

Completed Phase 2 Interventional Results available

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01071252

View directory record Official record

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: San Diego, California • Louisville, Kentucky • Rochester, New York + 2 more

Source: ClinicalTrials.gov public record

Updated Feb 15, 2015 · Synced May 21, 2026, 7:14 PM EDT